23. McCarty, Shickle L, Roberts CH, et al. 5-Azacytidine prior to allogeneic transplantation effectively reduces relapse, TRM and overall mortality in high risk myelodysplasia and secondary AML [abstract]. Bone Marrow Transplant. 2008;41 (suppl 1). Abstract #746. 24.Oliansky DM,Antin JH,Be...
Life expectancy is particularly poor for patients with an increased medullary blast infiltration (RAEB and RAEB/T), profound pancytopenia and abnormal cytogenetics (particularly complex aberrations and chromosome 7 anomalies). Allogeneic stem cell transplantation offers a potential cure for younger patients...
Findings from the phase 3 ASCERTAIN study (NCT03306264) identified that fixed-dose oral decitabine and cedazuridine (Inqovi) had pharmacologic equivalence to intravenously (IV) administered decitabine in patients with intermediate and high-risk myelodysplastic syndromes (MDS), including chronic myelomonocyti...
Currently, patients classified in the moderately high-, high- and very high-risk categories according to the IPSS-M should be rapidly transplanted [18] to ensure a longer life expectancy [19]. However, selecting eligible patients for transplantation has been a challenging subject over the last ...
This can help determine if you have lower-risk MDS, which may mean that you can live for years before you need treatment, or higher-risk MDS, which may mean a shorter life expectancy and more aggressive treatment. My MDS Diagnosis In the summer of 2018, Jon Hendren felt pretty good at...
Allogeneic stem cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia J Clin Oncol, 23 (2005), pp. 9387-9393 View in ScopusGoogle Scho...
The role of mesenchymal stromal cells (MSCs) in the pathogenesis of myelodysplastic syndromes (MDS) has been increasingly addressed, but has yet to be clearly elucidated. In this investigation, we found that MDS cells proliferated to a greater extent on
Follo MY, Finelli C, Mongiorgi S et al (2009) Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 106(39):16811–16816 Germing U, Gattermann N, Strupp C et al (2000) Validation of the WHO...
potentially associated with a reduced risk of progression to AML,18 the question of whether lenalidomide treatment confers an increased risk of progression to AML was raised by European regulatory authorities as a result of the seemingly high rate of AML progression observed in the MDS-003 study. ...
We first classified patients according to the IPSS score9: 29 (6%) patients had low, 134 (26%) had intermediate-1, 177 (34%) had intermediate-2, and 179 (34%) had high risk. In these risk groups, the 5-year OS was 66%, 61%, 33%, and 24%, respectively (P < .001; Figure...